|Mr. Michael Frank||Chairman & CEO||377.08k||N/A||1961|
|Mr. Carmelo Marrelli CPA, B.Comm., CA, CGA, ACIS||Chief Financial Officer||89.11k||N/A||1971|
|Dr. Kelly McKee Jr., M.P.H., M.D.||Chief Scientific Officer Consultant||N/A||N/A||N/A|
|Dr. Onesmo Mpanju Ph.D.||Chief Regulatory Affairs Consultant||N/A||N/A||N/A|
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers novel cannabinoid-centric treatments for liver diseases, inflammatory diseases, and skin disorders. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and coronavirus disease; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocybin oral formulations for the treatment of depression, anxiety, etc.; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has a research collaboration agreement with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; and with North Carolina State University for the development of a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Revive Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.